Phase II trial of Neu2000 in Korean patients with ischemic stroke
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 May 2016
At a glance
- Drugs NEU 2000 (Primary)
- Indications Stroke
- Focus Proof of concept; Therapeutic Use
- Acronyms ENIS I
- Sponsors GNT Pharma
- 16 May 2016 According to a GNT Pharma media release, this trial is expected to initiate in the second quarter of 2016 and to complete in 2017.
- 16 May 2016 According to a GNT Pharma media release, the Korea Ministry of Food and Drug Safety has approved the company's Investigational New Drug (IND) application to initiate a Phase II clinical study of Neu2000 in ischemic stroke patients receiving endovascular therapy.
- 16 May 2016 According to a GNT Pharma media release, status changed from planning to not yet recruiting.